Syndecan‐1 (CD138) contributes to prostate cancer progression by stabilizing tumour‐initiating cells
Authors:
- 20 September 2013
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 231 (4) , 495-504
Abstract
Increasing evidence suggests that tumour‐initiating cells (TICs) contribute to the development of prostate cancer. Here, we identified syndecan‐1 as a key molecule maintaining the stability of prostate cancer TICs. Holoclones harbouring the biological properties of stemness were derived from single‐cell cultures of the PC3 human prostate cancer cell line. These holoclones over‐expressed syndecan‐1, but showed reduced expression of NADPH oxidase (NOX) and synthesis of hydrogen peroxide and oxygen radicals. Stable RNA‐mediated silencing of syndecan‐1 gene expression up‐regulated NOX‐dependent generation of reactive oxygen species and reduced the survival of holoclones in vitro. Syndecan‐1 down‐regulation also strongly reduced the number of CD133+/CD44+ primitive cancer cells and tumour growth in vivo. Interestingly, syndecan‐1 gene knockdown significantly enhanced the tumour‐suppressive effects of docetaxel by inhibiting the docetaxel‐induced increase in CD133+/CD44+ cells in vivo. In the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model of prostate cancer, early intervention with a syndecan‐1 inhibitor (OGT2115) or syndecan‐1 RNAi reduced the incidence of adenocarcinoma and the number of c‐kit+/CD44+ cells in cancer foci. Finally, we found that syndecan‐1 immunopositivity in prostate cancer cells was significantly associated with biochemical recurrence after radical prostatectomy. Taken together, our results show that syndecan‐1 contributes to prostatic carcinogenesis by maintaining TICs and may be a target molecule for therapy. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 34 references indexed in Scilit:
- SIRT1 Is Essential for Oncogenic Signaling by Estrogen/Estrogen Receptor α in Breast CancerCancer Research, 2011
- ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladderBMC Urology, 2011
- ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancerBritish Journal of Cancer, 2011
- Microenvironmental Regulation of Glioblastoma RadioresponseClinical Cancer Research, 2010
- A NADPH Oxidase–Dependent Redox Signaling Pathway Mediates the Selective Radiosensitization Effect of Parthenolide in Prostate Cancer CellsCancer Research, 2010
- Function of JunB in Transient Amplifying Cell Senescence and Progression of Human Prostate CancerClinical Cancer Research, 2008
- The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyBlood, 2007
- Updated Nomogram to Predict Pathologic Stage of Prostate Cancer Given Prostate-Specific Antigen Level, Clinical Stage, and Biopsy Gleason Score (Partin Tables) Based on Cases from 2000 to 2005Urology, 2007
- Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myelomaOncogene, 2006
- Preoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical ProstatectomyJNCI: Journal of the National Cancer Institute, 2006